Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Abemaciclib,CCN1CCN(CC1)CC1=CC=C(NC2=NC=C(F)C(=N2)C2=CC3=C(N=C(C)N3C(C)C)C(F)=C2)N=C1,Liver injury,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 208716/S-000 Part 02, page:3 PDF 572k",https://www.pharmapendium.com/browse/fda/Abemaciclib/f42a829c35848fcfc7f39855ba4b2d51?reference=3,2017.0,CCN1CCN(CC1)CC1=CC=C(NC2=NC=C(F)C(=N2)C2=CC3=C(N=C(C)N3C(C)C)C(F)=C2)N=C1
Abiraterone Acetate,[H][C@@]12CC=C3C[C@H](CC[C@]3(C)[C@@]1([H])CC[C@]1(C)C(=CC[C@@]21[H])C1=CN=CC=C1)OC(C)=O,Liver injury,Human,-3.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202379/S-000 Part 04, page:30 PDF 1116k",https://www.pharmapendium.com/browse/fda/Abiraterone Acetate/c8b107b726c8a60d25ce0b1bfb7056a7?reference=30,2010.0,[H][C]12CC=C3C[CH](CC[C]3(C)[C]1([H])CC[C]1(C)C(=CC[C]21[H])C1=CN=CC=C1)OC(C)=O
Acetaminophen,CC(=O)NC1=CC=C(O)C=C1,Liver injury,Human,-0.9030899869919435,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 022450, page:47 PDF 2564k",https://www.pharmapendium.com/browse/fda/Acetaminophen/83f8128ea8e6ce0b48b9c4616e72f373?reference=47,2009.0,CC(=O)NC1=CC=C(O)C=C1
Alectinib Hydrochloride,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C2=O)C2=C(N1)C=C(C=C2)C#N,Liver injury,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 208434/S-000 Part 04, page:31 PDF 1103k",https://www.pharmapendium.com/browse/fda/Alectinib Hydrochloride/08016b74dd48063d91356464db4510cb?reference=31,2015.0,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C2=O)C2=C(N1)C=C(C=C2)C#N
Ambrisentan,COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1,Liver injury,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 022081/S-017 Part 05, page:46 PDF 6131k",https://www.pharmapendium.com/browse/fda/Ambrisentan/7eb36e2aef104a107f4e978fef0262de?reference=46,2011.0,COC([CH](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1
Apixaban,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O,Liver injury,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/478338/2014; EMEA/H/C/002148/II/0014/G, page:82 PDF 2588k",https://www.pharmapendium.com/browse/ema/Apixaban/63204c7b176325279d63eef03f2d71ff?reference=82,2014.0,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl,Liver injury,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Approval Package 021436/S-019, S-020, S-022; 021713/S-014 Part 11, page:7 PDF 469k",https://www.pharmapendium.com/browse/fda/Aripiprazole/fd3d55b51b2ac8211beb1b1f392661d5?reference=7,2008.0,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
Atorvastatin Calcium,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,Liver injury,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 020702/S-060 Part 04, page:14 PDF 4355k",https://www.pharmapendium.com/browse/fda/Atorvastatin Calcium/1d336d10697716750826d49291f8cc74?reference=14,2012.0,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[CH](O)C[CH](O)CC([O-])=O)C1=CC=C(F)C=C1
Benoxaprofen,CC(C(O)=O)C1=CC=C2OC(=NC2=C1)C1=CC=C(Cl)C=C1,Liver injury,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 018250 Part 04, page:75 PDF 10386k",https://www.pharmapendium.com/browse/fda/Benoxaprofen/b9ab0cdd250f97cd27dccfe2b18c1c91?reference=75,1976.0,CC(C(O)=O)C1=CC=C2OC(=NC2=C1)C1=CC=C(Cl)C=C1
Bicalutamide,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC=C(C#N)C(=C1)C(F)(F)F,Liver injury,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Label 022310/S-000, page:5 PDF 1277k",https://www.pharmapendium.com/browse/fda/Bicalutamide/5848b88922e842c26c1086584dabe239?reference=5,2008.0,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC=C(C#N)C(=C1)C(F)(F)F
Bosutinib Monohydrate,COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1,Liver injury,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Assessment Report EMA/70979/2013, page:69 PDF 1136k",https://www.pharmapendium.com/browse/ema/Bosutinib Monohydrate/ab40610c3303b50455387aeda860af0b?reference=69,2013.0,COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1
Brexpiprazole,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1,Liver injury,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205422/S-000 Part 04, page:93 PDF 20059k",https://www.pharmapendium.com/browse/fda/Brexpiprazole/00ccb22ace460844be09f496a697ac0d?reference=93,2014.0,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1
Buprenorphine,[H][C@@]1(C[C@]23CC[C@@]1(OC)[C@@H]1OC4=C(O)C=CC5=C4[C@]21CCN(CC1CC1)[C@@H]3C5)[C@](C)(O)C(C)(C)C,Liver injury,Human,-2.4771212547196626,Single,Subcutaneous,"FDA approval package document: Medical/Clinical Review 209819/S-000 Part 05, page:21 PDF 2301k",https://www.pharmapendium.com/browse/fda/Buprenorphine/8f1398455cffb93396afecba69bdf704?reference=21,2017.0,[H][C]1(C[C]23CC[C]1(OC)[CH]1OC4=C(O)C=CC5=C4[C]21CCN(CC1CC1)[CH]3C5)[C](C)(O)C(C)(C)C
Bupropion Hydrochloride,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,Liver injury,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Approval Package 018644/S-000 Part 05, page:13 PDF 3983k",https://www.pharmapendium.com/browse/fda/Bupropion Hydrochloride/e68800fc565636f246ca24af62d132f0?reference=13,1985.0,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1
Cabotegravir Sodium,[H][C@@]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[C@@H](C)CO2,Liver injury,Human,-1.7781512503836436,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/586324/2020; EMEA/H/C/004976/0000, page:134 PDF 8611k",https://www.pharmapendium.com/browse/ema/Cabotegravir Sodium/7d31e8568fdb1789517380a5b98893eb?reference=134,2020.0,[H][C]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[CH](C)CO2
Ceritinib,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1,Liver injury,Human,-2.8750612633917,Repeated,Oral,"EMA approval document: Assessment Report EMA/170114/2015; EMEA/H/C/003819/0000, page:86 PDF 3461k",https://www.pharmapendium.com/browse/ema/Ceritinib/625fcc14a77690a19eb6362758b85c7e?reference=86,2015.0,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
Cladribine,NC1=NC(Cl)=NC2=C1N=CN2[C@@H]1C[C@H](O)[C@@H](CO)O1,Liver injury,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022561/S-000 Part 01, page:7 PDF 892k",https://www.pharmapendium.com/browse/fda/Cladribine/8de2b2b3b466ab4b73d24494c3fefa90?reference=7,2010.0,NC1=NC(Cl)=NC2=C1N=CN2[CH]1C[CH](O)[CH](CO)O1
Clomipramine Hydrochloride,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C12,Liver injury,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Approval Package 019906/S-001, S-005, S-007, S-013, S-014, S-015, S-016 Part 01, page:23 PDF 4280k",https://www.pharmapendium.com/browse/fda/Clomipramine Hydrochloride/a2ee265d4f26e905e656c012bb37d71e?reference=23,1991.0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C12
Clozapine,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2,Liver injury,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Label 203479/S-000, page:27 PDF 1267k",https://www.pharmapendium.com/browse/fda/Clozapine/107c277867a1040822f8ad90fa780b3d?reference=27,2013.0,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2
Colchicine,COC1=CC=C2C(=CC1=O)[C@H](CCC1=CC(OC)=C(OC)C(OC)=C21)NC(C)=O,Liver injury,Human,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Label 204820/S-000, page:4 PDF 579k",https://www.pharmapendium.com/browse/fda/Colchicine/b5803a134c17b2d83f02bf3d034c4f02?reference=4,2014.0,COC1=CC=C2C(=CC1=O)[CH](CCC1=CC(OC)=C(OC)C(OC)=C21)NC(C)=O
Crizotinib,C[C@@H](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl,Liver injury,Human,-2.3979400086720375,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/465053/2015; EMEA/H/C/002489/II/0024, page:65 PDF 5392k",https://www.pharmapendium.com/browse/ema/Crizotinib/05eca3517bfe9024d37dbc98ba567512?reference=65,2015.0,C[CH](OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C(F)=CC=C1Cl
Dacomitinib,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,Liver injury,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/201148/2019; EMEA/H/C/004779/0000, page:134 PDF 7228k",https://www.pharmapendium.com/browse/ema/Dacomitinib/579cd00a268ddcd1d8cd19badb26782b?reference=134,2019.0,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Danazol,[H][C@@]12CCC3=CC4=C(C[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@@]1(O)C#C)C=NO4,Liver injury,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 017557/S-002, S-003, S-004, S-006 Part 02, page:44 PDF 4163k",https://www.pharmapendium.com/browse/fda/Danazol/97667b2cbb0a1bec203ef186413cc433?reference=44,1976.0,[H][C]12CCC3=CC4=C(C[C]3(C)[C]1([H])CC[C]1(C)[C]2([H])CC[C]1(O)C#C)C=NO4
Delamanid,C[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)N(=O)=O,Liver injury,Human,-2.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/55567/2014; EMEA/H/C/002552, page:91 PDF 4324k",https://www.pharmapendium.com/browse/ema/Delamanid/e0682a9e8072d93e83504aa96dac2c8e?reference=91,2013.0,C[C]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)N(=O)=O
Diclofenac Potassium,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Liver injury,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Label 022202/S-000, page:7 PDF 1085k",https://www.pharmapendium.com/browse/fda/Diclofenac Potassium/753bf335ec07dc33069381fe02214df7?reference=7,2010.0,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Diltiazem Hydrochloride,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,Liver injury,Human,-2.5563025007672873,Repeated,Oral,"FDA approval package document: Approval Package 020062/S-042 Part 01, page:15 PDF 305k",https://www.pharmapendium.com/browse/fda/Diltiazem Hydrochloride/0cb2e3110d81df28afe7a562e76e96f2?reference=15,2016.0,COC1=CC=C(C=C1)[CH]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[CH]1OC(C)=O
Dimethyl Fumarate,COC(=O)\C=C\C(=O)OC,Liver injury,Human,-2.8573324964312685,Repeated,Oral,"EMA approval document: Assessment Report EMA/412737/2017; EMEA/H/C/002157/0000, page:81 PDF 4381k",https://www.pharmapendium.com/browse/ema/Dimethyl Fumarate/b6e83e951426e8cba7410e9dd65532ac?reference=81,2017.0,COC(=O)\C=C\C(=O)OC
Diroximel Fumarate,COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O,Liver injury,Human,-2.6646419755561257,Repeated,Oral,"FDA approval package document: Label 211855/S-001, page:5 PDF 1115k",https://www.pharmapendium.com/browse/fda/Diroximel Fumarate/ec4bbe58d8b9fd093fee7ca551ffa5c2?reference=5,2019.0,COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O
Dofetilide,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,Liver injury,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 020931/S-013 Part 02, page:12 PDF 1015k",https://www.pharmapendium.com/browse/fda/Dofetilide/8cb981ebf1d43ef2d32d23093e710f83?reference=12,2016.0,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1
Dolutegravir Sodium,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,Liver injury,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Label 204790/S-000, page:1 PDF 547k",https://www.pharmapendium.com/browse/fda/Dolutegravir Sodium/142bf3dbfe0851e3f0de774d67a911a7?reference=1,2013.0,[H][C]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[CH](C)CCO2
Duloxetine Hydrochloride,CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1,Liver injury,Human,-2.0791812460476247,Repeated,Oral,"EMA approval document: ANNEX I, page:6 PDF 209k",https://www.pharmapendium.com/browse/ema/Duloxetine Hydrochloride/b89d9b2cc3a51c303012bfda8b61b474?reference=6,2020.0,CNCC[CH](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1
Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1,Liver injury,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 204629/S-008 Part 23, page:4 PDF 1147k",https://www.pharmapendium.com/browse/fda/Empagliflozin/f3b739b56adee05bf8c4e8c82cfbf1c5?reference=4,2015.0,OC[CH]1O[CH]([CH](O)[CH](O)[CH]1O)C1=CC(CC2=CC=C(O[CH]3CCOC3)C=C2)=C(Cl)C=C1
Eslicarbazepine Acetate,CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2,Liver injury,Human,-3.255272505103306,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022416/S-000 Part 11, page:32 PDF 765k",https://www.pharmapendium.com/browse/fda/Eslicarbazepine Acetate/90e7c2e2e973db3fa8122b77e814cea6?reference=32,2013.0,CC(=O)O[CH]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2
Etravirine,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N,Liver injury,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022187/S-000 Part 02, page:16 PDF 6254k",https://www.pharmapendium.com/browse/fda/Etravirine/23cba3104661ccebce18224813c53489?reference=16,2008.0,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
Febuxostat,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O,Liver injury,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: ANNEX I, page:24 PDF 300k",https://www.pharmapendium.com/browse/ema/Febuxostat/9263bc582cfb24cf942ce6af88777fab?reference=24,2019.0,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O
Fexofenadine Hydrochloride,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Liver injury,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201373/S-000 Part 11, page:34 PDF 876k",https://www.pharmapendium.com/browse/fda/Fexofenadine Hydrochloride/d7059e44b20a49f9940c212d18b49443?reference=34,2010.0,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Flucytosine,NC1=NC(=O)NC=C1F,Liver injury,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Label 017001/S-000, page:13 PDF 1236k",https://www.pharmapendium.com/browse/fda/Flucytosine/8b4c46f692806fc09b1eedcba617a43e?reference=13,2009.0,NC1=NC(=O)NC=C1F
Fluvastatin Sodium,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O,Liver injury,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 020261/S-046 Part 03, page:2 PDF 808k",https://www.pharmapendium.com/browse/fda/Fluvastatin Sodium/4845d89ec455c3d165fc7e5de2f27555?reference=2,2012.0,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[CH](O)C[CH](O)CC([O-])=O
Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,Liver injury,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 022484/S-000, page:5 PDF 493k",https://www.pharmapendium.com/browse/fda/Itraconazole/a3becfed4b8977e01e361d9159fde665?reference=5,2009.0,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
Ivosidenib,FC1=CN=CC(=C1)N([C@H](C(=O)NC1CC(F)(F)C1)C1=C(Cl)C=CC=C1)C(=O)[C@@H]1CCC(=O)N1C1=NC=CC(=C1)C#N,Liver injury,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 211192/S-000 Part 07, page:60 PDF 1425k",https://www.pharmapendium.com/browse/fda/Ivosidenib/dff8ff2fbdbaf7cb01b8640411f09c5c?reference=60,2018.0,FC1=CN=CC(=C1)N([CH](C(=O)NC1CC(F)(F)C1)C1=C(Cl)C=CC=C1)C(=O)[CH]1CCC(=O)N1C1=NC=CC(=C1)C#N
Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,Liver injury,Human,-3.0791812460476247,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/534845/2014; EMEA/H/C/003906/0000, page:65 PDF 1943k",https://www.pharmapendium.com/browse/ema/Ketoconazole/7021d14a92fb1a5a02778a5b85c49d37?reference=65,2014.0,[H][C]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl
Lacosamide,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1,Liver injury,Human,-1.0791812460476249,Repeated,Oral,"EMA approval document: Assessment Report EMA/381037/2015; EMEA/H/C/000863/P46/025, page:10 PDF 1086k",https://www.pharmapendium.com/browse/ema/Lacosamide/a74e585f3ed874ebc6eb439d7b8a1888?reference=10,2015.0,COC[CH](NC(C)=O)C(=O)NCC1=CC=CC=C1
Lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,Liver injury,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 208025/S-000 Part 05, page:18 PDF 574k",https://www.pharmapendium.com/browse/fda/Lansoprazole/acea02bfb0d22596b2a1c7287dd59bcc?reference=18,2015.0,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Lasofoxifene,OC1=CC=C2[C@H]([C@H](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1,Liver injury,Human,-1.0,Repeated,Oral,"EMA approval document: Assessment Report EMEA/14045/2009; EMEA/H/C/000977, page:38 PDF 1001k",https://www.pharmapendium.com/browse/ema/Lasofoxifene/fab9a90d9b1c1549313b9c76151f1eb1?reference=38,2013.0,OC1=CC=C2[CH]([CH](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1
Leflunomide,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Liver injury,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/478482/2013; EMEA/H/C/001227/X/0012/G, page:17 PDF 243k",https://www.pharmapendium.com/browse/ema/Leflunomide/8c5ee593d87230d2f1e5fca39db1ea67?reference=17,2013.0,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Liver injury,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: ANNEX I, page:94 PDF 639k",https://www.pharmapendium.com/browse/ema/Lenalidomide/25cd756533c94cddbdd01735140f5be1?reference=94,2021.0,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Liver injury,Human,-0.47712125471966244,Repeated,Subcutaneous,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 206321/S-000 Part 03, page:16 PDF 4929k",https://www.pharmapendium.com/browse/fda/Liraglutide/89607ebb61bab857867a252b0f96e5b3?reference=16,2014.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,Liver injury,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 019643/S-085 Part 02, page:2 PDF 3050k",https://www.pharmapendium.com/browse/fda/Lovastatin/642856c4d647d2fa991f52957462a577?reference=2,2012.0,[H][C]12[CH](C[CH](C)C=C1C=C[CH](C)[CH]2CC[CH]1C[CH](O)CC(=O)O1)OC(=O)[CH](C)CC
Macitentan,CCCNS(=O)(=O)NC1=C(C2=CC=C(Br)C=C2)C(OCCOC2=NC=C(Br)C=N2)=NC=N1,Liver injury,Human,-1.0,Repeated,Oral,"FDA approval package document: Label 204410/S-000, page:4 PDF 1037k",https://www.pharmapendium.com/browse/fda/Macitentan/e45922be3091f9f6b63a1a09d3103ffa?reference=4,2013.0,CCCNS(=O)(=O)NC1=C(C2=CC=C(Br)C=C2)C(OCCOC2=NC=C(Br)C=N2)=NC=N1
Maraviroc,[H][C@]12CC[C@]([H])(C[C@H](C1)N1C(C)=NN=C1C(C)C)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1,Liver injury,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022128/S-000, page:5 PDF 9351k",https://www.pharmapendium.com/browse/fda/Maraviroc/63de6af16da50e6623bc5d8a7d0aa587?reference=5,2007.0,[H][C]12CC[C]([H])(C[CH](C1)N1C(C)=NN=C1C(C)C)N2CC[CH](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Meloxicam,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O,Liver injury,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207233/S-000 Part 04, page:27 PDF 9738k",https://www.pharmapendium.com/browse/fda/Meloxicam/0caf0c63e10542b81af2c271442ab2d4?reference=27,2015.0,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O
Mesalamine,NC1=CC(C(O)=O)=C(O)C=C1,Liver injury,Human,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 022000/S-005 Part 02, page:116 PDF 14664k",https://www.pharmapendium.com/browse/fda/Mesalamine/6dd5c45b6e24648a96b0fc7c1fcf31af?reference=116,2011.0,NC1=CC(C(O)=O)=C(O)C=C1
Methylphenidate Hydrochloride,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,Liver injury,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205831/S-005 Part 03, page:51 PDF 2091k",https://www.pharmapendium.com/browse/fda/Methylphenidate Hydrochloride/a9b2f8f88331d9006254e1f21ac7b634?reference=51,2019.0,COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Liver injury,Human,-2.0,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021754/S-000, page:57 PDF 6745k",https://www.pharmapendium.com/browse/fda/Micafungin Sodium/7026a7089ecf0a3bc9dbeb1c5ccde6f9?reference=57,2005.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Minocycline Hydrochloride,[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,Liver injury,Human,-0.0,Repeated,Oral,"FDA approval package document: Approval Package 050808/S-014 Part 03, page:2 PDF 304k",https://www.pharmapendium.com/browse/fda/Minocycline Hydrochloride/141b93a4b2a2cae5e690a99717613a44?reference=2,2011.0,[H][C]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2
Mirabegron,NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1,Liver injury,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202611/S-000 Part 15, page:3 PDF 363k",https://www.pharmapendium.com/browse/fda/Mirabegron/47611d4dcef9b2acee814771a0e48d9f?reference=3,2012.0,NC1=NC(CC(=O)NC2=CC=C(CCNC[CH](O)C3=CC=CC=C3)C=C2)=CS1
Monomethyl Fumarate,COC(=O)\C=C\C(O)=O,Liver injury,Human,-2.278753600952829,Repeated,Oral,"FDA approval package document: Label 210296/S-001, page:5 PDF 692k",https://www.pharmapendium.com/browse/fda/Monomethyl Fumarate/07d78ac5e988c5116f279e8f437a6d8f?reference=5,2020.0,COC(=O)\C=C\C(O)=O
Montelukast Sodium,CC(C)(O)C1=CC=CC=C1CC[C@@H](SCC1(CC1)CC([O-])=O)C1=CC=CC(\C=C\C2=CC=C3C=CC(Cl)=CC3=N2)=C1,Liver injury,Human,-1.0,Repeated,Oral,"FDA approval package document: Label 020829/S-052; 020830/S-053; 021409/S-029, page:6 PDF 2196k",https://www.pharmapendium.com/browse/fda/Montelukast Sodium/c3507e14269d522ccc3bd8fd27c2c163?reference=6,2010.0,CC(C)(O)C1=CC=CC=C1CC[CH](SCC1(CC1)CC([O-])=O)C1=CC=CC(\C=C\C2=CC=C3C=CC(Cl)=CC3=N2)=C1
Naltrexone Hydrochloride,OC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5CC1CC1,Liver injury,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 018932/S-001, S-010, S-012 Part 01, page:11 PDF 5345k",https://www.pharmapendium.com/browse/fda/Naltrexone Hydrochloride/52b6f4f22a155ea6f7e87404296e21ae?reference=11,1984.0,OC1=C2O[CH]3C(=O)CC[C]4(O)[CH]5CC(C=C1)=C2[C]34CCN5CC1CC1
Nilotinib Hydrochloride Monohydrate,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F,Liver injury,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Assessment Report EMA/313746/2017; EMEA/H/C/000798/II/0084/G, page:66 PDF 2138k",https://www.pharmapendium.com/browse/ema/Nilotinib Hydrochloride Monohydrate/d01e77935612f8a2f5c9961a577b6a3b?reference=66,2017.0,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F
Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,Liver injury,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020592/S-000 Part 02, page:14 PDF 5147k",https://www.pharmapendium.com/browse/fda/Olanzapine/3eef21dddf583514b78b077669e8ec09?reference=14,1996.0,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Pazopanib Hydrochloride,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1,Liver injury,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022465/S-000, page:69 PDF 1560k",https://www.pharmapendium.com/browse/fda/Pazopanib Hydrochloride/893f6f8879191ff31ae434f60b8e4e98?reference=69,2009.0,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1
Pexidartinib Hydrochloride,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,Liver injury,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 211810/S-000 Part 07, page:40 PDF 855k",https://www.pharmapendium.com/browse/fda/Pexidartinib Hydrochloride/b8014b9a95e2f8615062ebf1f04be996?reference=40,2019.0,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
Pirfenidone,CC1=CN(C(=O)C=C1)C1=CC=CC=C1,Liver injury,Human,-0.47712125471966244,Repeated,Oral,"EMA approval document: ANNEX I, page:4 PDF 584k",https://www.pharmapendium.com/browse/ema/Pirfenidone/f226e169713c0421846663f628f4b284?reference=4,2020.0,CC1=CN(C(=O)C=C1)C1=CC=CC=C1
Pitavastatin Calcium,O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O,Liver injury,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 022363/S-008, S-009 Part 03, page:1 PDF 696k",https://www.pharmapendium.com/browse/fda/Pitavastatin Calcium/ea6bbc31c7abef908790ac73c5f7e399?reference=1,2012.0,O[CH](C[CH](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O
Ponatinib Hydrochloride,CN1CCN(CC1)CC1=C(C=C(NC(=O)C2=CC(C#CC3=CN=C4C=CC=NN34)=C(C)C=C2)C=C1)C(F)(F)F,Liver injury,Human,-1.6532125137753437,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 203469/S-000 Part 06, page:7 PDF 1752k",https://www.pharmapendium.com/browse/fda/Ponatinib Hydrochloride/6ba0cf1dd0203d9b5f4a5e4470ffbb65?reference=7,2012.0,CN1CCN(CC1)CC1=C(C=C(NC(=O)C2=CC(C#CC3=CN=C4C=CC=NN34)=C(C)C=C2)C=C1)C(F)(F)F
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@@](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1,Liver injury,Human,-2.4771212547196626,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 205596/S-000 Part 03, page:27 PDF 679k",https://www.pharmapendium.com/browse/fda/Posaconazole/113fa8836f55665474696b01ff5473be?reference=27,2013.0,CC[CH]([CH](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[CH]2CO[C](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1
Pramipexole Dihydrochloride,CCCN[C@H]1CCC2=C(C1)SC(N)=N2,Liver injury,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022514/S-000 Part 15, page:4 PDF 472k",https://www.pharmapendium.com/browse/fda/Pramipexole Dihydrochloride/575ae229cbcdb9c8e44d2ea636ec39ce?reference=4,2009.0,CCCN[CH]1CCC2=C(C1)SC(N)=N2
Pravastatin Sodium,[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC([O-])=O)OC(=O)[C@@H](C)CC,Liver injury,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 019898/S-062 Part 01, page:41 PDF 1214k",https://www.pharmapendium.com/browse/fda/Pravastatin Sodium/9cd2ea8d0b260d57f67d92089d7b101f?reference=41,2012.0,[H][C]12[CH](C[CH](O)C=C1C=C[CH](C)[CH]2CC[CH](O)C[CH](O)CC([O-])=O)OC(=O)[CH](C)CC
Rabeprazole Sodium,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1,Liver injury,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020973/S-009 Part 02, page:96 PDF 14721k",https://www.pharmapendium.com/browse/fda/Rabeprazole Sodium/6b3f55d6bf0ad42f82ef4ae04d59ca5e?reference=96,2002.0,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1
Raltegravir Potassium,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1,Liver injury,Human,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205786; 203045/S-009; 022145/S-031 Part 03, page:24 PDF 479k",https://www.pharmapendium.com/browse/fda/Raltegravir Potassium/e28f9d31e64a0028bae6154b8c35cc77?reference=24,2013.0,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Regorafenib,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,Liver injury,Human,-2.2041199826559246,Repeated,Oral,"FDA approval package document: Administrative documents 203085/S-000 Part 01, page:41 PDF 3318k",https://www.pharmapendium.com/browse/fda/Regorafenib/950ac20ee465ed3d165b769badab6224?reference=41,2012.0,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
Remdesivir,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1,Liver injury,Human,-2.3010299956639813,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 214787/S-000 Part 03, page:29 PDF 1237k",https://www.pharmapendium.com/browse/fda/Remdesivir/27efae85ef2e8d3460cff7dde5014c8d?reference=29,2020.0,CCC(CC)COC(=O)[CH](C)N[P](=O)(OC[CH]1O[C](C#N)([CH](O)[CH]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1
Riluzole,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1,Liver injury,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 020599/S-011 Part 01, page:13 PDF 358k",https://www.pharmapendium.com/browse/fda/Riluzole/574e4a8501e51da4f7704c1c56c447b3?reference=13,2006.0,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Liver injury,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022406/S-000 Part 14, page:5 PDF 473k",https://www.pharmapendium.com/browse/fda/Rivaroxaban/1b0338783fe0856b60ba3409330c086d?reference=5,2009.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Rosuvastatin Calcium,CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1,Liver injury,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 021366/S-024 Part 03, page:18 PDF 933k",https://www.pharmapendium.com/browse/fda/Rosuvastatin Calcium/fd6f850669161bf26eb7261f0808b3aa?reference=18,2012.0,CC(C)C1=C(\C=C\[CH](O)C[CH](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1
Sotorasib,CC(C)C1=NC=CC(C)=C1N1C(=O)N=C(N2CCN(C[C@@H]2C)C(=O)C=C)C2=CC(F)=C(N=C12)C1=C(O)C=CC=C1F,Liver injury,Human,-2.9822712330395684,Repeated,Oral,"FDA approval package document: Label 214665/S-001, page:5 PDF 805k",https://www.pharmapendium.com/browse/fda/Sotorasib/c5664fac0861ff234e58ece9a54e2869?reference=5,2021.0,CC(C)C1=NC=CC(C)=C1N1C(=O)N=C(N2CCN(C[CH]2C)C(=O)C=C)C2=CC(F)=C(N=C12)C1=C(O)C=CC=C1F
Strontium Ranelate,[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O,Liver injury,Human,-3.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/PRAC/136656/2013, page:27 PDF 2811k",https://www.pharmapendium.com/browse/ema/Strontium Ranelate/bda34774e61b135741ca19f8a9844c5e?reference=27,2013.0,[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O
Tadalafil,[H][C@]12CC3=C(NC4=C3C=CC=C4)[C@H](N1C(=O)CN(C)C2=O)C1=CC=C2OCOC2=C1,Liver injury,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 021368/S-020 Part 24, page:12 PDF 298k",https://www.pharmapendium.com/browse/fda/Tadalafil/a2783dd21bdffc66c1d02e874f59ae62?reference=12,2011.0,[H][C]12CC3=C(NC4=C3C=CC=C4)[CH](N1C(=O)CN(C)C2=O)C1=CC=C2OCOC2=C1
Telbivudine,CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O,Liver injury,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022154/S-000 Part 01, page:93 PDF 6217k",https://www.pharmapendium.com/browse/fda/Telbivudine/fae0e1c84415df1f2cae1dd239c0bc14?reference=93,2009.0,CC1=CN([CH]2C[CH](O)[CH](CO)O2)C(=O)NC1=O
Telithromycin,[H][C@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1,Liver injury,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 021144/S-012, page:44 PDF 657k",https://www.pharmapendium.com/browse/fda/Telithromycin/3525544120b4529175fd8596ec3552c0?reference=44,2007.0,[H][C]12[CH](C)C(=O)[CH](C)C[C](C)(OC)[CH](O[CH]3O[CH](C)C[CH]([CH]3O)N(C)C)[CH](C)C(=O)[CH](C)C(=O)O[CH](CC)[C]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1
Teriflunomide,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Liver injury,Human,-0.8450980400142568,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202992/S-000 Part 12, page:57 PDF 11938k",https://www.pharmapendium.com/browse/fda/Teriflunomide/9711c01cf59f491dbbc62266f7c8962f?reference=57,2012.0,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Tigecycline,[H][C@@]12CC3=C(C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C,Liver injury,Human,-1.6989700043360187,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/CHMP/183367/2011; EMEA/H/C/000644/R/0053, page:18 PDF 465k",https://www.pharmapendium.com/browse/ema/Tigecycline/d3877e43a961ce0aa933fbebe1ad1288?reference=18,2011.0,[H][C]12CC3=C(C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2)C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C
Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,Liver injury,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204441/S-000 Part 04, page:46 PDF 6589k",https://www.pharmapendium.com/browse/fda/Tolvaptan/1855f2995f8ec9e519b7402d7140e3ad?reference=46,2013.0,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2
Tucatinib,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1,Liver injury,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 213411/S-000 Part 09, page:10 PDF 598k",https://www.pharmapendium.com/browse/fda/Tucatinib/3ddeabbb47ced7d45d65277796f95289?reference=10,2020.0,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1
Ulipristal Acetate,[H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C,Liver injury,Human,-1.0,Repeated,Oral,"EMA approval document: ANNEX, page:3 PDF 45k",https://www.pharmapendium.com/browse/ema/Ulipristal Acetate/3669cf22e099153f138560d846af72e8?reference=3,2018.0,[H][C]12CCC3=CC(=O)CCC3=C1[CH](C[C]1(C)[C]2([H])CC[C]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C
Vemurafenib,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,Liver injury,Human,-2.9822712330395684,Repeated,Oral,"EMA approval document: ANNEX I, page:11 PDF 363k",https://www.pharmapendium.com/browse/ema/Vemurafenib/8f68826a3e60e626b5097d6ded0b7aa6?reference=11,2021.0,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
Vigabatrin,NC(CCC(O)=O)C=C,Liver injury,Human,-3.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020427/S-000 Part 05, page:12 PDF 5259k",https://www.pharmapendium.com/browse/fda/Vigabatrin/5b87b86505ab0944591ede43aff19214?reference=12,2009.0,NC(CCC(O)=O)C=C
Vismodegib,CS(=O)(=O)C1=CC=C(C(=O)NC2=CC=C(Cl)C(=C2)C2=CC=CC=N2)C(Cl)=C1,Liver injury,Human,-2.1760912590556813,Single,Oral,"EMA approval document: ANNEX I, page:34 PDF 419k",https://www.pharmapendium.com/browse/ema/Vismodegib/28e9b8058c092accf061ecbc58b59d96?reference=34,2020.0,CS(=O)(=O)C1=CC=C(C(=O)NC2=CC=C(Cl)C(=C2)C2=CC=CC=N2)C(Cl)=C1
Voriconazole,C[C@@H](C1=C(F)C=NC=N1)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Liver injury,Human,-1.0791812460476249,Repeated,Oral/intravenous,"FDA approval package document: Medical/Clinical Review 021266/S-039 Part 04, page:10 PDF 403k",https://www.pharmapendium.com/browse/fda/Voriconazole/fad8c008eb4d37c3a8fe4b35fa6dba24?reference=10,2017.0,C[CH](C1=C(F)C=NC=N1)[C](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F
Zafirlukast,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C,Liver injury,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Label 020547/S-029, page:8 PDF 1194k",https://www.pharmapendium.com/browse/fda/Zafirlukast/244ecd1e992ff73be2fed108af9f0eb5?reference=8,2009.0,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C
Zanamivir,[H][C@]1(OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO,Liver injury,Human,-2.7781512503836434,Repeated,Intravenous,"EMA approval document: Medicine Overview EMA/161401/2019; EMEA/H/C/004102, page:2 PDF 77k",https://www.pharmapendium.com/browse/ema/Zanamivir/04dadc21d827d8eed0b5ab3fe48f24b7?reference=2,2019.0,[H][C]1(OC(=C[CH](NC(N)=N)[CH]1NC(C)=O)C(O)=O)[CH](O)[CH](O)CO
